The drugs will be sold at zero profit to governments in up to 79 eligible countries until a vaccine or treatment for COVID-19 is available. To be eligible, countries have to be on the World Bank’s list of low-income of lower-middle income countries.
Novartis will supply the following drugs:
- Amoxicillin
- Ceftriaxone
- Clarithromycin
- Colchicine
- Dexamethasone
- Dobutamine
- Fluconazole
- Heparin
- Levofloxacin
- Loperamide
- Pantoprazole
- Prednisone
- Prednisolone
- Salbutamol
- Vancomycin
The drugs were chosen based on clinical relevance and availability to make sure demand can be met globally. Participating countries can choose which medicines to receive.
Novartis said it started the initiative because the COVID-19 pandemic has placed extreme pressure on healthcare systems in low- and lower middle-income countries.
“The COVID-19 response portfolio for low-income and lower-middle-income countries is designed to support governments in treating COVID-19 symptoms before they lead to complications in patients,” said Richard Saynor, president of Novartis’ Sandoz unit.
Read the full news release here.
More articles on pharmacy:
Moderna COVID-19 vaccine spurs immune response, initial data shows
Almost ‘like hurricane season’: Florida Walgreens pharmacy manager describes pandemic chaos
Sun Pharma faces retaliation lawsuit from former sales rep, its third in a year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
